Immunogenic fusion proteins for the treatment of cancer
US9808516B2 · kind B2 · utility
6Cited by
6References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 12, 2016 |
| Grant date | Nov 7, 2017 |
| Priority date | — |
| Expiry date | Apr 12, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.